全文获取类型
收费全文 | 321413篇 |
免费 | 23628篇 |
国内免费 | 1362篇 |
专业分类
耳鼻咽喉 | 3649篇 |
儿科学 | 8384篇 |
妇产科学 | 5665篇 |
基础医学 | 42343篇 |
口腔科学 | 5351篇 |
临床医学 | 32779篇 |
内科学 | 68144篇 |
皮肤病学 | 4189篇 |
神经病学 | 31201篇 |
特种医学 | 11089篇 |
外国民族医学 | 11篇 |
外科学 | 49857篇 |
综合类 | 4245篇 |
一般理论 | 396篇 |
预防医学 | 26714篇 |
眼科学 | 8405篇 |
药学 | 21700篇 |
5篇 | |
中国医学 | 441篇 |
肿瘤学 | 21835篇 |
出版年
2023年 | 1754篇 |
2022年 | 2719篇 |
2021年 | 7565篇 |
2020年 | 4471篇 |
2019年 | 7221篇 |
2018年 | 8207篇 |
2017年 | 6049篇 |
2016年 | 6630篇 |
2015年 | 7758篇 |
2014年 | 11423篇 |
2013年 | 15439篇 |
2012年 | 23735篇 |
2011年 | 24822篇 |
2010年 | 13872篇 |
2009年 | 12316篇 |
2008年 | 21353篇 |
2007年 | 22309篇 |
2006年 | 21835篇 |
2005年 | 21816篇 |
2004年 | 20269篇 |
2003年 | 18796篇 |
2002年 | 17471篇 |
2001年 | 2676篇 |
2000年 | 2000篇 |
1999年 | 2851篇 |
1998年 | 3781篇 |
1997年 | 3082篇 |
1996年 | 2610篇 |
1995年 | 2484篇 |
1994年 | 2117篇 |
1993年 | 1953篇 |
1992年 | 1518篇 |
1991年 | 1354篇 |
1990年 | 1200篇 |
1989年 | 1149篇 |
1988年 | 1137篇 |
1987年 | 1078篇 |
1986年 | 1090篇 |
1985年 | 1109篇 |
1984年 | 1396篇 |
1983年 | 1273篇 |
1982年 | 1585篇 |
1981年 | 1539篇 |
1980年 | 1299篇 |
1979年 | 808篇 |
1978年 | 862篇 |
1977年 | 735篇 |
1976年 | 655篇 |
1975年 | 533篇 |
1974年 | 524篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献82.
Harinakshi Sanikini David C. Muller Marisa Sophiea Sabina Rinaldi Antonio Agudo Eric J. Duell Elisabete Weiderpass Kim Overvad Anne Tjønneland Jytte Halkjær Marie-Christine Boutron-Ruault Franck Carbonnel Iris Cervenka Heiner Boeing Rudolf Kaaks Tilman Kühn Antonia Trichopoulou Georgia Martimianaki Anna Karakatsani Valeria Pala Domenico Palli Amalia Mattiello Rosario Tumino Carlotta Sacerdote Guri Skeie Charlotta Rylander María-Dolores Chirlaque López Maria-Jose Sánchez Eva Ardanaz Sara Regnér Tanja Stocks Bas Bueno-de-Mesquita Roel C.H. Vermeulen Dagfinn Aune Tammy Y.N. Tong Nathalie Kliemann Neil Murphy Marc Chadeau-Hyam Marc J. Gunter Amanda J. Cross 《International journal of cancer. Journal international du cancer》2020,146(4):929-942
Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for 476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models. During a mean follow-up of 14 years, 220 esophageal adenocarcinomas (EA), 195 esophageal squamous cell carcinomas, 243 gastric cardia (GC) and 373 gastric noncardia (GNC) cancers were diagnosed. Body mass index (BMI) was associated with EA in men (BMI ≥30 vs. 18.5–25 kg/m2: HR = 1.94, 95% CI: 1.25–3.03) and women (HR = 2.66, 95% CI: 1.15–6.19); however, adjustment for waist-to-hip ratio (WHR) attenuated these associations. After mutual adjustment for BMI and HC, respectively, WHR and waist circumference (WC) were associated with EA in men (HR = 3.47, 95% CI: 1.99–6.06 for WHR >0.96 vs. <0.91; HR = 2.67, 95% CI: 1.52–4.72 for WC >98 vs. <90 cm) and women (HR = 4.40, 95% CI: 1.35–14.33 for WHR >0.82 vs. <0.76; HR = 5.67, 95% CI: 1.76–18.26 for WC >84 vs. <74 cm). WHR was also positively associated with GC in women, and WC was positively associated with GC in men. Inverse associations were observed between parity and EA (HR = 0.38, 95% CI: 0.14–0.99; >2 vs. 0) and age at first pregnancy and GNC (HR = 0.54, 95% CI: 0.32–0.91; >26 vs. <22 years); whereas bilateral ovariectomy was positively associated with GNC (HR = 1.87, 95% CI: 1.04–3.36). These findings support a role for hormonal pathways in upper gastrointestinal cancers. 相似文献
83.
Michael A. Gibney David Fitz-Patrick David C. Klonoff Shahista Whooley Betty Lu Wen Yue 《Current medical research and opinion》2020,36(10):1591-1600
Abstract
Objective
Two similarly designed studies compared user experiences with a second-generation extra-thin-wall, 5-bevel 32?G?×?4?mm pen needle (PN) with redesigned hub versus four thinner commercially available PNs. 相似文献84.
85.
86.
87.
Suchi Raghunathan Corey L. Reynolds Robert J. Schwartz M. David Stewart Bradley K. McConnell 《Fundamental & clinical pharmacology》2019,33(1):25-30
Inbred mouse strains are the most widely used mammalian model organism in biomedical research owing to ease of genetic manipulation and short lifespan; however, each inbred strain possesses a unique repertoire of deleterious homozygous alleles that can make a specific strain more susceptible to a particular disease. In the current study, we report dystrophic cardiac calcinosis (DCC) in C.B‐17 SCID male mice at 10 weeks of age with no significant change in cardiac function. Acquisition of DCC was characterized by myocardial injury, fibrosis, calcification, and necrosis of the tissue. At 10 weeks of age, 38% of the C.B‐17 SCID mice from two different commercial colonies exhibited significant calcinosis on the ventricular epicardium, predominantly on the right ventricle. The frequency of calcinosis was more than 50% for mice obtained from Taconic's Cambridge City colony and 25% for mice obtained from Taconic's German Town colony. Interestingly, the DCC phenotype did not affect cardiac function at 10 weeks of age. No differences in echocardiography or electrocardiography were observed between the calcinotic and non‐calcinotic mice from either colony. Our findings suggest that C.B‐17 SCID mice exhibit DCC as early as 10 weeks of age with no significant impact on cardiac function. This strain of mice should be cautiously considered for the study of cardiac physiology. 相似文献
88.
89.
90.